EUCTR2021-003466-12-DE进行中（未招募）1 期
A double-blind, randomised, multi-centre, controlled clinical trial to compare D-mannose versus antibiotic in the treatment of acute uncomplicated lower urinary tract infections in female patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Female outpatients aged 18 to 70 years
- •2.Clinical signs and symptoms of an acute uncomplicated cystitis (e.g. dysuria, pollakisuria, and / or urgency to urinate) starting not earlier than 72 hours prior to trial enrolment at Visit 1
- •3.Signed informed consent and data protection form
- •4.ACSS-Typical” domain score is =6 at Visit 1
- •5.Urine dipstick test (midstream sample) is positive for leukocytes at Visit 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 112
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •2.Pregnant or lactating females or females of childbearing potential who are not using an effective method of contraception
- •3.Females with episodes of acute cystitis within 4 weeks before enrolment (Visit 1) or females with =3 episodes of acute cystitis within 6 months before enrolment
- •4.Anamnestic proof of presence of any predisposing factors or any conditions that may promote or lead to (complicated) urinary tract infections (i.e., anamnestic proof of renal insufficiency, renal calculi, polycystic kidneys, urinary tract abnormalities or past urinary surgery, urine catheterisation, spinal cord injury, etc.)
- •5.Anamnestic proof of renal impairment (creatinine clearance <30 mL / min)
- •6.Anamnestic proof of diabetes mellitus (Type I and II)
- •7.Any signs of pyelonephritis (i.e., fever =38.0°C tympanic, flank and / or back pain, chills or shivers)
- •8.Vulvovaginitis with abnormal vaginal and / or with urethral discharge (without urination) at Visit 1
- •9.Known or suspected hypersensitivity to one or more of the ingredients of the test product (Femannose® N) and / or comparator (Fosfomycin HEXAL®) and / or any placebo used
- •10.Systemic or local (i.e. vaginal) treatment with antibiotics within 7 days prior to Visit 1
- •11.Treatment with analgesics (e.g. nonsteroidal anti-inflammatory drugs, NSAIDs) within 6 hours prior to Visit 1
- •12.Parallel participation in another clinical study or trial, participation in a clinical study or trial within the previous 4 weeks prior to Visit 1, or previous participation in this clinical trial
- •13.Known to be or suspected of being unable to comply with the trial protocol (e.g. no permanent address, history of or (and) known drug abuse, known to be non-compliant or presenting an unstable psychiatric history)
- •14.Legal incapacity and / or other circumstances which makes the subject unable to understand the nature, scope and possible impact of the investigation
- •15.Custody by juridical or official order
- •16.Evidence of an uncooperative attitude (non-compliance)
- •17.Difficulties in understanding the language in which the informed consent and data protection declaration is given
- •18.Investigational site staff, staff of the sponsor or involved clinical research organisation (CRO), the investigator him- / herself or close relatives
研究者
相似试验
进行中（未招募）
1 期
Does Rifaximin reduce the risk of infection for patients admitted to hospital with liver disease?Decompensated cirrhosis - liver diseaseEUCTR2016-002628-96-GBImperial College London268
进行中（未招募）
1 期
a clinical study for patients suffering from chronic venous leg ulcers to be treated with a new wound healing solutioVenous leg ulcer (ulcus cruris)MedDRA version: 18.0Level: LLTClassification code 10045346Term: Ulcerated varicose veinsSystem Organ Class: 100000004866EUCTR2014-001001-40-LTDermaTools Biotech GmbH160
进行中（未招募）
1 期
a clinical study for patients suffering from chronic venous leg ulcers to be treated with a new wound healing solutioEUCTR2014-001001-40-LVDermaTools Biotech GmbH160
进行中（未招募）
不适用
A multi-center, randomized, double-blind, controlled Phase III study of the efficacy and safety of an oxygen-carrying colloid and plasma expander, Hemospan, compared with colloid (Voluven) for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia - 6090 Treatment StudyTreatment of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesiaMedDRA version: 8.1Level: LLTClassification code 10021097Term: HypotensionEUCTR2006-002514-35-NLSangart, Inc.460
进行中（未招募）
不适用
A multi-center, randomized, double-blind, controlled Phase III study of the efficacy and safety of an oxygen-carrying colloid and plasma expander, Hemospan, compared with colloid (Voluven) for treatment of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia - 6090 Treatment StudyTreatment of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesiaMedDRA version: 8.1Level: LLTClassification code 10021097Term: HypotensionEUCTR2006-002514-35-SESangart, Inc.460